PHARMACEUTICALS +++

PHARMACEUTICALS MedPage Today: Gene Therapy Supply Runs Out, Company Warns Of Treatment Delays https://www.medpagetoday.com/hematologyoncology/hemophilia/120410?utm_campaign=KHN%3A%20First%20Edition&utm_medium=email&_hsenc=p2ANqtz-8u-mNMKUy8khny53Y6xXfxaQc_6-dWV06XH3ql6Xh6PmtNFZK4HMHLBMBGSPjx592NsXE9Hve_eSS9AJlXgkFvhJx-zQ&_hsmi=410057768&utm_content=410057768&utm_source=hs_email Etranacogene dezaparvovec (Hemgenix), the only commercially available gene therapy for hemophilia B, is temporarily unavailable, according to maker CSL Behring. In a letter addressed to the hemophilia B community, the company said it is experiencing a "temporary global stockout" of the one-time gene therapy that will result in treatment delays for some patients in countries where the product is approved, including the U.S. (Bassett, 3/21) Stat: FDA Approved C. Diff Drugs. Access To Treatment Got Harder https://www.statnews.com/2026/03/23/c-diff-fda-drug-approval-access-paradox-fecal-transplants/?utm_campaign=KHN%3A%20First%20Edition&utm_medium=email&_hsenc=p2ANqtz--cpveUnFydM1PkFUUQ9ttHoGbDK7vklJSmfEhxVLSQBf2dxEq046ZXStgSKTlM8da7d91jLIvyf6XEJrnu5b9KAl-vEw&_hsmi=410057768&utm_content=410057768&utm_source=hs_email Her son had been sick for four months when Blanca Morales started asking about a transplant. It had started with a case of strep throat from Mundo’s first-grade class — routine enough, treatable with antibiotics. Then he started having stomach trouble. (Boodman, 3/23) Modern Healthcare: Abbott Laboratories To Close $21B Exact Sciences Deal Monday https://www.modernhealthcare.com/medical-devices/mh-abbott-laboratories-exact-sciences-acquisition-closed/?utm_campaign=KHN%3A%20First%20Edition&utm_medium=email&_hsenc=p2ANqtz-_TZ2A_G45fsxzIZ5mFLd_H97vjQB7-0yJelHoaWd9BpFldym4xRlUg7BAjrzt3Nyuxjsw1tqPRQUTznOPmXIUzx0Huhg&_hsmi=410057768&utm_content=410057768&utm_source=hs_email Abbott Laboratories said Friday it plans to close its acquisition of cancer-screening company Exact Sciences Corp. on Monday. The deal was announced in November, with a total equity value of approximately $21 billion. At the time, the companies said Exact Sciences would become a subsidiary of Abbott and Abbott’s total diagnostic sales would surpass $12 billion annually as a result of the purchase. The transaction is anticipated to add about $3 billion of incremental sales in 2026. (Dubinsky, 3/20)